Methocarbamol

CHEMBL1201117 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
241.2 g/mol
LogP
0.6
Phase
4

A centrally acting muscle relaxant used to relieve pain and spasms associated with acute musculoskeletal conditions, typically as an adjunct to rest and physical therapy. It works by depressing the central nervous system.

Masse moléculaire

241,2400 g/mol

LogP

0,60

TPSA

91,00 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1ccccc1OCC(O)COC(N)=O

InChI

InChI=1S/C11H15NO5/c1-15-9-4-2-3-5-10(9)16-6-8(13)7-17-11(12)14/h2-5,8,13H,6-7H2,1H3,(H2,12,14)

Molecular Formula

C11H15NO5

HBD / HBA

2 / 5

Liaisons Rotatives

7

Atomes Lourds

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A centrally acting muscle relaxant used to relieve pain and spasms associated with acute musculoskeletal conditions, typically as an adjunct to rest and physical therapy. It works by depressing the central nervous system.

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Yes, Methocarbamol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201117. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 4107. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.